维持性泼尼松治疗视神经脊髓炎的疗效观察  

An open label study of the effects of oral prednisone on neuromyelitis optica

作　　者：吴萱[1] 林艾羽[1] 王华燕[1] 魏慧星[1] 王丹妮[1] 王柠[1] 

机构地区：[1]福建医科大学附属第一医院神经内科,福州350005

出　　处：《中国神经精神疾病杂志》2015年第3期145-149,共5页Chinese Journal of Nervous and Mental Diseases

基　　金：国家临床重点专科建设项目和福建省临床重点专科建设项目

摘　　要：目的观察维持性泼尼松治疗视神经脊髓炎(neuromyelitis optica,NMO)的疗效及安全性。方法对17例复发型NMO患者进行随访,观察在维持性泼尼松治疗前后,患者的扩展残疾状态量表(expanded disability status scale,EDSS)评分、年复发率的变化以及治疗期间出现的不良反应。结果经维持性泼尼松治疗后,患者的EDSS评分较治疗前改善[(3.09±0.85)vs.(4.06±0.80)],差异有统计学意义(P<0.05);年复发率较治疗前明显下降[(0.34±0.31)次/年vs.(1.51±0.57)次/年],差异有统计学意义(P<0.005);但不同剂量泼尼松对于年复发率降低水平的影响差异无统计学意义。随访期间无严重不良反应出现。结论维持性泼尼松治疗能有效降低NMO患者的年复发率,并改善其神经功能缺失情况,有较好的耐受性。Objective To evaluate the efficacy and safety of oral prednisone in patients with relapsing neuromyeli-tis optica. Methods Seventeen patients with relapsing neuromyelitis optica receiving long-term oral prednisone had been followed. The Expanded Disability Status Scale （EDSS） and annualized relapse rates were used to evaluate curative effect. Results During long-term oral prednisone treatment, patients had a significant reduction in the EDSS [（3.09 ± 0.85） vs. （4.06 ± 0.80）, P〈0.05] and the median annualized relapse rate was significant reduced [（0.34 ± 0.31） vs. （1.51 ± 0.57）, P〈0.005]. But the effect of different dosage of prednisone on annualized relapse rates was not different. No severe adverse re-actions were observed. Conclusions Treatment with long-term oral prednisone in patients with NMO significantly reduces relapse rates, improves neurological function and the treatment was well-tolerated.

关 键 词：视神经脊髓炎 泼尼松 治疗 

分 类 号：R744.52[医药卫生—神经病学与精神病学]